Table 3 Lymph node status in 584 endometrial cancer patients subjected to lymphadenectomy in relation to clinicopathological variables and expression of biomarkers

From: DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer

Variable Category Lymph node negative Lymph node positive P -value
Age <66 Years 279 87.7% 39 12.3%  
  ≥66 Years 233 87.6% 33 12.4% 0.959
Information available preoperatively
Curettage histology classificationa Low risk 406 91.4% 38 8.6%  
  High risk 103 75.2% 34 24.8% <0.001
Curettage DNA ploidyb Diploid 381 90.9% 38 9.1%  
  Non-diploid 131 79.4% 34 20.6% <0.001
Information available postoperatively
Histological subtypec Endometrioid 446 91.8% 40 8.2%  
(hysterectomy specimen) Non-endometrioid 64 66.7% 32 33.3% <0.001
Histological gradec Grades 1 and 2 384 93.0% 29 7.0%  
(hysterectomy specimen) Grade 3 127 75.1% 42 24.9% <0.001
Myometrial infiltrationd <50% 334 97.7% 8 2.3%  
(hysterectomy specimen) ≥50% 157 79.7% 40 20.3% <0.001
  1. Abbreviation: FIGO=International Federation of Gynaecology and Obstetrics.
  2. All P-values are by Pearson’s χ2 test.
  3. aCurettage histological risk classification as either low risk (benign, hyperplasia, or endometrioid grades 1–2) or High risk (comprising non-endometrioid or endometrioid grade 3 histology).
  4. bNon-diploid comprising aneuploidy, tetraploid, and polyploidy curettage.
  5. cHistological subtype and grade missing for two patients.
  6. dMyometrial infiltration available for 539 patients.